東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

What Are the Best Treatments for Pro...

Tian, Yu.

Linked to FindBook

Google Book

Amazon

博客來

What Are the Best Treatments for Proliferative Lupus Nephritis.

Record Type:	Electronic resources : Monograph/item
Title/Author:	What Are the Best Treatments for Proliferative Lupus Nephritis./
Author:	Tian, Yu.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
Description:	240 p.
Notes:	Source: Dissertations Abstracts International, Volume: 80-02, Section: B.
Contained By:	Dissertations Abstracts International80-02B.
Subject:	Biostatistics. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10688551
ISBN:	9780438189584

What Are the Best Treatments for Proliferative Lupus Nephritis.
Tian, Yu.

What Are the Best Treatments for Proliferative Lupus Nephritis. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 240 p.

Source: Dissertations Abstracts International, Volume: 80-02, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2018.

This item must not be sold to any third party vendors.

Background. Trial evidence, in adults, examining the relative effectiveness of immunosuppressive agents in the treatment of proliferative lupus nephritis (PLN) has been controversial. Trial evidence is sparse, particularly lacking long-term data, because trials are very difficult to do in this disease (due to its rarity and heterogeneous manifestations). There is no trial data to inform pediatric treatment. Observational treatment studies are limited by indication bias. A class of causal models, marginal structural models (MSMs), has been recommended in the literature to estimate treatment effectiveness using observational data, while correcting for indication bias. In order to determine the most effective immunosuppressive therapy for this disease, we designed and conducted this project. Methods. Systematic reviews and Bayesian network meta-analyses of trial evidence were performed. A MSM was used for an unbiased estimate of treatment effectiveness for childhood-onset PLN (cPLN). Results. Mycophenolate mofetil (MMF), in addition to prednisone, is the most effective therapy in the treatment of PLN, both in the short-term and long-term use, based on current evidence. Our pediatric findings were consistent with adult evidence and suggestive of MMF's superiority over other agents. Tacrolimus seemed better than MMF for adults in inducing renal remission at 6 months, but it has been insufficiently examined in other geographical regions than Asia. The probability of inducing renal remission for the best therapy was about 50% or lower at 6 months. Interestingly, the probability of preventing renal death at 2-3 years for azathioprine used at the current dose was second only to MMF. The 6% improvement in renal function, on average over a period of about 4 years in cPLN, induced by MMF versus other immunosuppressive agents (while correcting for indication bias) was statistically significant (p = 0.02). Conclusions. Whereas the evidence may not be sufficient to be definitive, MMF appears to be the best treatment for PLN. More studies are needed. Future clinical trials need to use a standardized conduct protocol and have a longer study duration. Future observational treatment studies should consider using MSM, especially for children and youth for rare diseases where clinical trials are infeasible.

ISBN: 9780438189584Subjects--Topical Terms:

1002712
Biostatistics.

What Are the Best Treatments for Proliferative Lupus Nephritis.
LDR:03422nmm a2200337 4500 001 2210269
005 20191121124156.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438189584
035 $a (MiAaPQ)AAI10688551
035 $a (MiAaPQ)toronto:17017
035 $a AAI10688551
040 $a MiAaPQ $c MiAaPQ
100 1 $a Tian, Yu. $3 3282452
245 1 0 $a What Are the Best Treatments for Proliferative Lupus Nephritis.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 240 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-02, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Feldman, Brian M.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2018.
506 $a This item must not be sold to any third party vendors.
520 $a Background. Trial evidence, in adults, examining the relative effectiveness of immunosuppressive agents in the treatment of proliferative lupus nephritis (PLN) has been controversial. Trial evidence is sparse, particularly lacking long-term data, because trials are very difficult to do in this disease (due to its rarity and heterogeneous manifestations). There is no trial data to inform pediatric treatment. Observational treatment studies are limited by indication bias. A class of causal models, marginal structural models (MSMs), has been recommended in the literature to estimate treatment effectiveness using observational data, while correcting for indication bias. In order to determine the most effective immunosuppressive therapy for this disease, we designed and conducted this project. Methods. Systematic reviews and Bayesian network meta-analyses of trial evidence were performed. A MSM was used for an unbiased estimate of treatment effectiveness for childhood-onset PLN (cPLN). Results. Mycophenolate mofetil (MMF), in addition to prednisone, is the most effective therapy in the treatment of PLN, both in the short-term and long-term use, based on current evidence. Our pediatric findings were consistent with adult evidence and suggestive of MMF's superiority over other agents. Tacrolimus seemed better than MMF for adults in inducing renal remission at 6 months, but it has been insufficiently examined in other geographical regions than Asia. The probability of inducing renal remission for the best therapy was about 50% or lower at 6 months. Interestingly, the probability of preventing renal death at 2-3 years for azathioprine used at the current dose was second only to MMF. The 6% improvement in renal function, on average over a period of about 4 years in cPLN, induced by MMF versus other immunosuppressive agents (while correcting for indication bias) was statistically significant (p = 0.02). Conclusions. Whereas the evidence may not be sufficient to be definitive, MMF appears to be the best treatment for PLN. More studies are needed. Future clinical trials need to use a standardized conduct protocol and have a longer study duration. Future observational treatment studies should consider using MSM, especially for children and youth for rare diseases where clinical trials are infeasible.
590 $a School code: 0779.
650 4 $a Biostatistics. $3 1002712
650 4 $a Medicine. $3 641104
650 4 $a Health sciences. $3 3168359
690 $a 0308
690 $a 0564
690 $a 0566
710 2 $a University of Toronto (Canada). $b Medical Science. $3 3182952
773 0 $t Dissertations Abstracts International $g 80-02B.
790 $a 0779
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10688551